DuChemBio Co, LTD
Founded 2002, KOSDAQ-listed 2024, DuChemBio makes radiopharmaceuticals FDG, FP-CIT, Neuraceq, and Vizamyl.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureDuChemBio was founded in 2002 and listed on KOSDAQ in December 2024 as a developer, manufacturer, and seller of radiopharmaceuticals. Its main products include FDG injection, FP-CIT injection, Neuraceq injection (florbetaben), Vizamyl injection (flutemetamol), and an 18F-FDOPA injection, and in August 2024 the company completed acquisition of 100% equity in Radio D&S Labs, a radiopharmaceutical R&D firm. DuChemBio operates 12 manufacturing sites, including 6 GMP-certified facilities, and in 2025 posted revenue of KRW 38,572 million (up 8.3% year-on-year) and operating profit of KRW 7,443 million (up 46.6%), with the FDG product line accounting for 57.1% of sales, the Alzheimer's diagnostic product line 19.4%, and the FP-CIT product line 9.9%.
Products & technology
- FDG injectionDiagnosis of tumors with glucose metabolism
- FP-CIT injectionMeasurement of striatal dopamine transporter density for diagnosis of Parkinson's disease and Parkinsonian syndrome
- Neuraceq injection (18F-florbetaben)Measurement of beta-amyloid distribution and density for Alzheimer's diagnosis
- Vizamyl injection (18F-flutemetamol)Measurement of beta-amyloid distribution and density for Alzheimer's diagnosis
- 18F-FDOPA injectionDiagnosis of brain tumors and neuroendocrine tumors; diagnosis of Parkinson's disease and differentiation of Parkinsonian syndrome
Regulatory approvals
data.go.kr10 Korean MFDS drug approvals · 2004–2025
- MFDS drugDuchembio_FES_injection(Fluoro Estradiol (18F) liq.)2025-12-18Drug · Prescription · Approval202503306
- MFDS drugProstaseek injection(Flotufolastat F18 liq.)2025-07-22Drug · Prescription · Approval202501845
- MFDS drugDuchembio FP-CIT injection2025-01-21Drug · Prescription · Approval202500157
- MFDS drugFACBC injecton2021-09-17Drug · Prescription · Approval202106591
- MFDS drugDopaceq Injection2019-10-22Drug · Prescription · Approval201907382
- MFDS drugVizamyl(flutemetamol(18F)2015-08-25Drug · Prescription · Approval201506003
- MFDS drugMetascan Injection2015-01-30Drug · Prescription · Approval201500482
- MFDS drugDuchembio FDG-102013-03-06Drug · Prescription · Approval201306043
- MFDS drugDuchembio FDG Pre-filled Syringe Injection2011-01-03Drug · Prescription · Approval201100003
- MFDS drugDuchembio FDG-20Revoked2004-09-06Drug · Prescription · Approval200404907
Companies in the same categoryPharma & CDMO
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition